Japanese Healthtech Stock News

TSE:3193
TSE:3193Hospitality

Eternal Hospitality GroupLtd (TSE:3193) EPS Slide To ¥25 Challenges Bullish Growth Narratives

Eternal Hospitality GroupLtd (TSE:3193) has posted its Q2 2026 numbers with revenue of ¥12.8 billion and basic EPS of ¥25.03, alongside net income of ¥288.78 million, giving investors a clear snapshot of mid year trading. The company has seen quarterly revenue move from ¥11.2 billion in Q2 2025 to ¥12.8 billion in Q2 2026, while basic EPS shifted from ¥28.28 to ¥25.03 over the same period, and investors will be weighing these trends against the latest margin picture and how efficiently those...
TSE:3159
TSE:3159Specialty Retail

Maruzen CHI Holdings (TSE:3159) Margin Compression To 1.8% Tests Bullish Narratives

Maruzen CHI HoldingsLtd (TSE:3159) has wrapped up FY 2026 with fourth quarter revenue of ¥43.3b and basic EPS of ¥2.47, rounding out a year where quarterly revenue ranged between ¥43.1b and ¥49.3b and EPS moved from ¥17.29 in Q1 to ¥2.47 in Q4. Across the latest trailing twelve months, revenue came in at ¥185.1b with basic EPS of ¥36.03, which may encourage investors to focus less on headline growth stories and more on how the business is converting that top line into earnings. With trailing...
TSE:4996
TSE:4996Chemicals

Kumiai Chemical Industry Q1 Margin Compression Challenges Bullish Earnings Growth Narrative

Kumiai Chemical Industry (TSE:4996) has opened fiscal 2026 with Q1 revenue of ¥46,707 million and basic EPS of ¥32.74, setting a fresh reference point after a volatile run of quarterly earnings. The company has seen revenue move from ¥43,381 million in Q1 2025 to ¥46,707 million in Q1 2026, while basic EPS shifted from ¥33.25 to ¥32.74 over the same periods. This gives investors a clean snapshot of the top and bottom line as they weigh how a thinner 2.5% trailing net margin and that prior...
TSE:7741
TSE:7741Medical Equipment

Assessing Whether HOYA (TSE:7741) Still Looks Expensive After Strong Multi Year Returns

Why HOYA is on investors’ radar today HOYA (TSE:7741) has attracted attention after recent share price moves, with the stock up over the past 3 years and 5 years while posting mixed returns over the past week and month. See our latest analysis for HOYA. At a share price of ¥27,765, HOYA’s recent 7 day and 30 day share price returns of 2.61% and 2.44% declines contrast with a stronger 90 day share price return of 16.2% and a 1 year total shareholder return of 61.74%. This suggests longer term...
TSE:9697
TSE:9697Entertainment

Did Capcom’s (TSE:9697) Resident Evil PC Tie-in and Leadership Shuffle Just Reframe Its IP Strategy?

GIGABYTE recently announced a collaboration with Capcom to promote the upcoming Resident Evil Requiem game through a themed custom PC giveaway and bundled monitor-game offers, while Capcom’s board approved director changes and new management roles effective April 1, 2026. Together, the gaming hardware tie-in and leadership reshuffle highlight how Capcom is leaning on flagship IP while refining its internal business focus. We’ll now examine how the Resident Evil Requiem collaboration with...
TSE:9984
TSE:9984Wireless Telecom

Reassessing SoftBank Group (TSE:9984) After Recent Share Price Slide And AI Narrative Shifts

Wondering whether SoftBank Group's current share price actually lines up with its underlying value? This article walks through the numbers so you can see how the market is pricing the story. The stock closed at ¥3,578 after an 8.9% decline over the last 7 days, a 24.0% drop over 30 days and a 22.5% fall year to date, while the 1 year return sits at 83.4% and the 3 year return is very large at about 3x. These swings have come as SoftBank Group continues to be closely watched as a major...
TSE:4502
TSE:4502Pharmaceuticals

Takeda Pharmaceutical (TSE:4502) Valuation Check After Strong 1 Year Return And Conflicting Fair Value Signals

Takeda Pharmaceutical stock snapshot Takeda Pharmaceutical (TSE:4502) has drawn investor attention after a period of steady trading, with its share price around ¥5,673 and multi year total returns along with recent revenue and net income figures in focus. See our latest analysis for Takeda Pharmaceutical. At around ¥5,673 per share, Takeda Pharmaceutical has delivered a 90 day share price return of 27.54%, while its 1 year total shareholder return of 33.82% points to building momentum beyond...
TSE:6702
TSE:6702IT

Fujitsu’s AI Infrastructure Alliance With Arrcus and 1Finity Could Be A Game Changer For Fujitsu (TSE:6702)

In early March 2026, Arrcus announced a collaboration with Fujitsu and 1Finity to combine FUJITSU-MONAKA Arm-based CPUs, ArcOS software-defined networking, and high-speed optical interconnects into a secure, energy-efficient infrastructure for distributed AI workloads from edge inference to large-scale training. This partnership highlights Fujitsu’s push to align compute, networking, and optical transport for emerging Physical and enterprise AI use cases such as smart factories, robotics,...
TSE:8002
TSE:8002Trade Distributors

Assessing Marubeni’s Valuation As The Branford Castle Partnership Expands Global Investment Reach

Why Marubeni’s Branford Castle deal matters for shareholders Marubeni (TSE:8002) has drawn investor attention after committing capital to Branford Castle Partners’ new flagship fund and agreeing to work alongside the firm to source and support global investment opportunities. See our latest analysis for Marubeni. The Branford Castle agreement lands while Marubeni’s share price sits at ¥5,591, with a 1 day share price return of 4.02% and 7 day return of 3.86%. However, the 30 day share price...
TSE:6645
TSE:6645Electronic

Omron’s SF2030 Plan Targets Data Growth In Automation And Healthcare

OMRON (TSE:6645) has released its SF2030 2nd Stage medium term plan, outlining a broad shift toward data driven operations. The plan highlights increased focus on industrial automation, healthcare, and targeted growth in Europe. This roadmap sets out multi year priorities for redirecting investment and reshaping the company’s business mix. OMRON, trading at ¥4,532.0, enters this new phase after a mixed share price record, with a 13.4% return year to date and a 3.5% return over 1 year,...
TSE:5801
TSE:5801Electrical

Is Furukawa Electric’s (TSE:5801) Leadership Reshuffle Quietly Redefining Its Core Technology Strategy?

Furukawa Electric has announced extensive executive transfers, new duties, and board director candidates following its March 5 Board of Directors meeting, with many changes taking effect from April 1 and further transitions planned through June 26, 2026. The reshuffle concentrates leadership around key domains such as digital infrastructure components, automotive systems, and energy infrastructure, suggesting a sharpened focus on technology-driven and infrastructure-related businesses. Next,...
TSE:4118
TSE:4118Chemicals

Does Kaneka’s Toro 88 Superbore Catheter Launch Deepen Its Neurovascular Ambitions For Kaneka (TSE:4118)?

Toro Neurovascular previously announced that the U.S. FDA had granted 510(k) clearance for its Toro 88 Superbore Catheter, with Kaneka Medical America LLC leading the U.S. commercial launch following the device’s first successful clinical use by Dr. Satoshi Tateshima. This launch underscores Kaneka’s deeper involvement in the neurovascular device market, pairing Toro’s catheter technology with Kaneka’s established U.S. sales and clinical support network. We’ll now examine how Kaneka’s role...
TSE:8058
TSE:8058Trade Distributors

How Frontier Lithium’s PAK MOU Could Shape Mitsubishi’s North American Battery Role (TSE:8058)

In March 2026, Frontier Lithium announced it had signed a non-binding Memorandum of Understanding with Panasonic Energy and Mitsubishi to explore lithium hydroxide procurement and broader collaboration around the PAK Lithium Project in Ontario, aimed at supplying North America’s electric vehicle battery supply chain from 2030. A key insight is that Mitsubishi’s existing joint venture role in the PAK Lithium Project now sits within a wider potential offtake and technical cooperation framework...
TSE:6920
TSE:6920Semiconductor

Lasertec (TSE:6920) Is Up 12.7% After Surprise Surge In Chip Inspection Tool Orders – What's Changed

In March 2026, Lasertec drew heightened attention after reports of stronger-than-expected order momentum for its semiconductor inspection and wafer metrology equipment, following a sharp sector-wide selloff tied to inflation concerns. This sequence of macro-driven weakness followed by renewed product-focused interest highlights how quickly sentiment can swing around Lasertec’s core inspection business. We’ll now examine how this stronger-than-expected order momentum for semiconductor...
TSE:3407
TSE:3407Chemicals

Is Asahi Kasei (TSE:3407) Still Attractive After Its Strong Multi Year Share Price Run

If you are wondering whether Asahi Kasei is still good value after its recent run, you are not alone. The key question now is how the current share price lines up with the underlying business. The stock closed at ¥1,616.5, with returns of 13.8% year to date, 60.5% over 1 year, 94.7% over 3 years and 38.5% over 5 years, although it has seen a 5.6% decline over the last 7 days and a 6.9% decline over the last 30 days. Recent news coverage around Asahi Kasei has focused on its position in the...
TSE:4151
TSE:4151Pharmaceuticals

Kyowa Kirin (TSE:4151) Valuation Check After Rocatinlimab Trials Are Halted Over Safety Concerns

Kyowa Kirin (TSE:4151) has moved to discontinue all clinical trials of rocatinlimab after a planned safety review highlighted malignancy concerns linked to OX40 pathway modulation, including confirmed and suspected Kaposi’s sarcoma cases. See our latest analysis for Kyowa Kirin. At a share price of ¥2,339, Kyowa Kirin has seen a 1-day share price return of 1.56% and a 7-day gain of 3.89%, compared with a weaker 30-day share price return of a 10.11% decline and a year-to-date share price...
TSE:7011
TSE:7011Machinery

The Bull Case For Mitsubishi Heavy Industries (TSE:7011) Could Change Following New U.S. Waste-Heat Projects

Mitsubishi Heavy Industries group company Turboden America was previously selected by Tallgrass to supply three Waste Heat-to-Power ORC plants at gas compressor stations in Ohio and Indiana, each expected to deliver around 10 MW of clean electricity and qualify for Inflation Reduction Act Investment Tax Credit incentives. This contract expands Mitsubishi Heavy Industries’ waste-heat-to-power footprint in the U.S., adding to its clean, reliable baseload power portfolio while potentially...
TSE:9692
TSE:9692Software

Computer Engineering & Consulting (TSE:9692) EPS Surge Reinforces Quality Earnings Narrative

Computer Engineering & Consulting (TSE:9692) has posted its FY 2026 results with fourth quarter revenue of ¥18.6b and basic EPS of ¥51.56, backed by net income of ¥1,609m. The company’s quarterly revenue moved from ¥14.99b in FY 2025 Q4 to ¥18.6b in FY 2026 Q4, while basic EPS in those periods went from ¥23.72 to ¥51.56. This highlights higher earnings that put more focus on how sustainably it can defend and build its margins. See our full analysis for Computer Engineering & Consulting. With...
TSE:8306
TSE:8306Banks

Is Mitsubishi UFJ Financial Group (TSE:8306) Offering Value After Recent Share Price Pullback?

If you are wondering whether Mitsubishi UFJ Financial Group's current share price reflects its true worth, this article will walk you through what the numbers are really saying about value. The stock trades at ¥2,656 after a 3.8% decline over the last 7 days and a 12.5% decline over the last 30 days, while the 1 year return sits at 37.2%. The 3 year and 5 year returns are also very large. Recent coverage has focused on Mitsubishi UFJ Financial Group as one of Japan's largest banking groups,...
TSE:6387
TSE:6387Semiconductor

Samco H1 2026 Earnings Growth Reinforces Bullish Narratives Despite Premium P E Concerns

SAMCO (TSE:6387) has released its H1 2026 scorecard, posting revenue of ¥4,587 million and basic EPS of ¥93.50, with net income excluding extra items at ¥751 million setting the tone for the latest update. The company has seen revenue move from ¥4,121 million with EPS of ¥88.89 in H1 2025 to ¥5,221 million and EPS of ¥122.39 in H2 2025, and trailing twelve month figures now sit at ¥9,808 million of revenue and EPS of ¥215.88, giving you a clear run rate to compare against the current half...
TSE:7777
TSE:7777Biotechs

3-D Matrix (TSE:7777) Profitability Swing In Q3 2026 Tests Rich P/E Narrative

3-D Matrix (TSE:7777) has just posted its Q3 2026 scorecard, with revenue of ¥2,539 million and net income of ¥653 million, translating to basic EPS of ¥5.39. The company has seen quarterly revenue range from ¥1,875 million in Q4 2025 to ¥2,613 million in Q2 2026, while basic EPS has swung from a loss of ¥10.11 in Q4 2025 to a gain of ¥7.96 in Q2 2026 and ¥5.39 this quarter. This reflects a move from losses to profits over the recent reporting periods. For investors, that combination of...
TSE:6594
TSE:6594Electrical

A Look At Nidec (TSE:6594) Valuation After Dividend Suspension And Accounting Governance Findings

Nidec (TSE:6594) is back in focus after its board resolved to skip the year end dividend for the fiscal year ending March 2026, following a Third Party Committee report on inappropriate accounting treatment. See our latest analysis for Nidec. The latest decision to skip the year end dividend comes on top of a 14.96% 3 month share price return and a 10.56% year to date share price return. At the same time, the 1 year total shareholder return of 13.24% and 5 year total shareholder return of...
TSE:4568
TSE:4568Pharmaceuticals

The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following ENHERTU’s Priority Review Success

In March 2026, Daiichi Sankyo and AstraZeneca announced that the U.S. FDA accepted and granted Priority Review to their supplemental Biologics License Application for ENHERTU, targeting adults with HER2 positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. The application rests on DESTINY-Breast05 phase 3 data showing ENHERTU cut the risk of invasive disease recurrence or death versus T-DM1, with three-year invasive disease-free survival of...
TSE:7201
TSE:7201Auto

Is There Now An Opportunity In Nissan Motor (TSE:7201) After Recent Share Price Weakness

If you are wondering whether Nissan Motor's current share price reflects its true worth, you are not alone, many investors are asking the same question as they reassess the stock. The shares recently closed at ¥381.4, with a 2.1% gain over the last 7 days contrasting with a 6.8% decline over 30 days and a 10.2% decline over 1 year, which can change how investors think about both upside and risk. Recent headlines around Nissan often focus on its position in the global auto sector and how it...